Macrolide resistance among invasive Streptococcus pneumoniae isolates

JAMA

Volumn 286, Issue 15, 2001, Pages 1857-1862

  Hyde, Terri B ^a,b   Gay, Kathryn ^c   Stephens, David S ^c   Vugia, Duc J ^d   Pass, Margaret ^e   Johnson, Susan ^f   Barrett, Nancy L ^g   Schaffner, William ^h   Cieslak, Paul R ⁱ   Maupin, Peggy S ^j   Zell, Elizabeth R ^a   Jorgensen, James H ^k   Facklam, Richard R ^a   Whitney, Cynthia G ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d California Department of Health   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f MINNESOTA DEPARTMENT OF HEALTH   (United States)

^g CDC   (United States)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ Oregon Health Division   (United States)

^j Monroe County Department of Public Health   (United States)

^k UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINCOMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFAMETHOXAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; FEMALE; HUMAN; INFECTION CONTROL; MALE; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; UNITED STATES;

EID: 0035904366     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.15.1857     Document Type: Article

References (35)

1. Practice guidelines for the management of community-acquired pneumonia in adults
2. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the drug-resistant Streptococcus pneumoniae therapeutic working group
3. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
4. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
5. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
6. Prevalence of antimicrobial resistance among respiratory isolates of Streptococcus pneumoniae in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program
7. Emergence of drug-resistant pneumococcal infections in the United States
8. Increasing prevelance of multidrug-resistant Streptococcus pneumoniae in the United States: A report from multistate, population-based surveillance
9. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system
10. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae
11. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural elements that regulate expression - A review
12. Origin and evolution of genes specifying resistance to macrolide, lincosamide and streptogramin antibiotics: Data and hypotheses
13. Nomenclature for macrolide and macrolide-lincosamide streptogramin B resistance determinants
14. Use of clindamycin disks to detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children
15. Pneumococcal macrolide resistance - Myth or reality?
16. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment
17. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era
18. Macrolide resistance in Belgian Streptococcus pneumoniae
19. Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy
20. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America
21. Emergence of M phenotype of erythromycin-resistant pneumococci in South Africa
22. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995
23. Distribution of mefE and ermB genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics
24. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection
25. Microbiologic activity of the newer macrolide antibiotics
26. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin
27. High prevalance of multidrug resistant Streptococcus pneumoniae among children in a rural Kentucky community
28. Colonization with penicillin-resistant Streptococcus pneumoniae in a child-care center
29. Streptococcus pneumoniae colonization in the young child: Association with otitis media and resistance to penicillin
30. Trends in antimicrobial drug prescribing among office-based physicians in the United States
31. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland: Finnish study group for antimicrobial resistance